Please ensure Javascript is enabled for purposes of website accessibility

How ImmunoGen Trounced Analysts' Q4 Revenue and Earnings Estimates

By Keith Speights - Feb 12, 2021 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company can thank its partner, Jazz Pharmaceuticals.

If you liked the gains generated by ImmunoGen (IMGN 2.44%) in 2020, you're loving the stock in 2021. So far this year, the biotech's shares have soared 32%. And that momentum is now likely to build even more.

ImmunoGen announced its fourth-quarter results before the market opened on Friday. Investors liked what they saw. Here are the highlights of ImmunoGen's Q4 update.

Scientist holding two test tubes

Image source: Getty Images.

By the numbers

ImmunoGen reported revenue in the fourth quarter of $85.8 million. This reflected a 91% jump from revenue of $44.9 million in the prior-year period. This result blew past the Wall Street consensus estimate of $40.8 million.

The drugmaker reported net income in the fourth quarter of $31.4 million, or $0.16 per share, based on generally accepted accounting principles (GAAP). This was a massive improvement over GAAP earnings of $4.8 million, or $0.03 per share, posted in the same quarter of 2019. It was also much better than the average analyst estimate of a Q4 net loss of $0.08 per share.

ImmunoGen ended the fourth quarter with cash, cash equivalents, and short-term investments of $239.9 million. This was an increase from the $176.2 million on hand as of Dec. 30, 2019.

Behind the numbers

Most of ImmunoGen's revenue in the fourth quarter came from license and milestone fees of $62.4 million. This amount was more than double the total from the prior-year period. The big jump stemmed from the recognition of $60.5 million in up-front fees already received from the biotech's collaboration with Jazz Pharmaceuticals, which recently announced plans to acquire GW Pharmaceuticals

ImmunoGen also reported noncash royalty revenue of $23.4 million in the fourth quarter. In the prior-year period, the company's noncash royalty revenue totaled $15.3 million. This growth was driven by increasing sales of breast cancer drug Kadcyla, which is marketed by Roche

The company's total operating expenses in Q4 jumped 35% year over year to $49.3 million. However, the added revenue from the big up-front fee from Jazz more than offset this increase, resulting in a significantly improved bottom line.

Looking ahead

ImmunoGen expects that revenue for full-year 2021 will be between $65 million and $75 million. The company anticipates operating expenses of $200 million to $210 million. It also projects cash and cash equivalents of between $140 million and $150 million at the end of this year, which should be enough to carry the company into the second half of 2022.

The biotech stock could have a major catalyst on the way later this year. ImmunoGen expects to report top-line results from its late-stage study of mirvetuximab soravtansine in ovarian cancer in the third quarter. If those results are positive, the company plans to file for U.S. regulatory approval by the end of 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$4.61 (2.44%) $0.11
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$42.01 (0.72%) $0.30
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$158.58 (1.65%) $2.57
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.